Richard Segal


+1 617 937 2332

Richard Segal represents high growth companies, investment banking firms and venture capital firms in public offerings and private placements of securities, with a focus on the technology and life sciences sectors. In addition to a robust domestic practice, he has significant experience in transactions involving foreign issuers seeking to access the U.S. capital markets. Rich also regularly counsels both U.S. and non-U.S. publicly-held companies with respect to corporate governance, SEC reporting and securities law compliance and advises private companies on a wide variety of general corporate and securities matters.

Download full bio 


  • Prelude – $182 Million IPO 

  • C4 Therapeutics – $210 Million IPO 

  • COMPASS Pathways – $147 Million IPO 

  • Inhibrx – $137 Million IPO 

  • ADC Therapeutics – $233 Million IPO 

  • View all


  • Boston College Law School
    JD, cum laude, 2009

  • Dartmouth College
    AB, cum laude, 2005

Admissions & Credentials


Rankings & Accolades

    Massachusetts Super Lawyers: Rising Star – Securities & Corporate Finance (2013 – 2016)


+1 617 937 2332 office

500 Boylston Street
14th Floor
Boston, MA 02116-3736